Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.16
BMRN's Cash-to-Debt is ranked lower than
79% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. BMRN: 1.16 )
Ranked among companies with meaningful Cash-to-Debt only.
BMRN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.21 Max: No Debt
Current: 1.16
Equity-to-Asset 0.69
BMRN's Equity-to-Asset is ranked higher than
53% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BMRN: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
BMRN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.4  Med: 0.6 Max: 0.95
Current: 0.69
-0.4
0.95
Piotroski F-Score: 3
Altman Z-Score: 6.63
Beneish M-Score: -2.75
WACC vs ROIC
14.13%
-25.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -71.94
BMRN's Operating Margin % is ranked higher than
53% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. BMRN: -71.94 )
Ranked among companies with meaningful Operating Margin % only.
BMRN' s Operating Margin % Range Over the Past 10 Years
Min: -71.94  Med: -12.42 Max: 13.41
Current: -71.94
-71.94
13.41
Net Margin % -56.43
BMRN's Net Margin % is ranked higher than
55% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. BMRN: -56.43 )
Ranked among companies with meaningful Net Margin % only.
BMRN' s Net Margin % Range Over the Past 10 Years
Min: -56.43  Med: -15.44 Max: 54.7
Current: -56.43
-56.43
54.7
ROE % -26.21
BMRN's ROE % is ranked higher than
57% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. BMRN: -26.21 )
Ranked among companies with meaningful ROE % only.
BMRN' s ROE % Range Over the Past 10 Years
Min: -26.21  Med: -9.05 Max: 39.6
Current: -26.21
-26.21
39.6
ROA % -17.17
BMRN's ROA % is ranked higher than
61% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. BMRN: -17.17 )
Ranked among companies with meaningful ROA % only.
BMRN' s ROA % Range Over the Past 10 Years
Min: -17.17  Med: -4.87 Max: 18.88
Current: -17.17
-17.17
18.88
ROC (Joel Greenblatt) % -85.51
BMRN's ROC (Joel Greenblatt) % is ranked higher than
64% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. BMRN: -85.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMRN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -89.45  Med: -11.53 Max: 31.1
Current: -85.51
-89.45
31.1
3-Year Revenue Growth Rate 19.10
BMRN's 3-Year Revenue Growth Rate is ranked higher than
70% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. BMRN: 19.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BMRN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.4  Med: 13.2 Max: 97.3
Current: 19.1
-10.4
97.3
3-Year EBITDA Growth Rate 61.80
BMRN's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BMRN: 61.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMRN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.2  Med: 25.65 Max: 424.8
Current: 61.8
-45.2
424.8
3-Year EPS without NRI Growth Rate 43.80
BMRN's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. BMRN: 43.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMRN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.75 Max: 43.8
Current: 43.8
0
43.8
GuruFocus has detected 2 Warning Signs with Biomarin Pharmaceutical Inc $BMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMRN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BMRN Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 139,920 sh (New)
Joel Greenblatt 3,144 sh (New)
Eaton Vance Worldwide Health Sciences Fund 370,500 sh (New)
RS Investment Management 24,250 sh (+14.82%)
Jim Simons Sold Out
Andreas Halvorsen Sold Out
PRIMECAP Management 7,319,319 sh (-0.42%)
Frank Sands 10,918,317 sh (-5.56%)
John Griffin 800,000 sh (-20.00%)
» More
Q3 2016

BMRN Guru Trades in Q3 2016

Ray Dalio 8,926 sh (New)
Jana Partners 52,890 sh (New)
George Soros 5,734 sh (New)
Steven Cohen 153,700 sh (New)
Andreas Halvorsen 490,304 sh (New)
Manning & Napier Advisors, Inc 142,410 sh (+1.78%)
John Griffin 800,000 sh (unchged)
Joel Greenblatt Sold Out
PRIMECAP Management 7,108,129 sh (-2.89%)
Frank Sands 10,221,282 sh (-6.38%)
Eaton Vance Worldwide Health Sciences Fund 292,429 sh (-21.07%)
» More
Q4 2016

BMRN Guru Trades in Q4 2016

Jim Simons 39,371 sh (New)
Manning & Napier Advisors, Inc 2,027,930 sh (+1324.01%)
Steven Cohen 526,600 sh (+242.62%)
Andreas Halvorsen 1,398,457 sh (+185.22%)
Jana Partners 93,923 sh (+77.58%)
PRIMECAP Management 7,885,948 sh (+10.94%)
Eaton Vance Worldwide Health Sciences Fund 292,429 sh (unchged)
George Soros Sold Out
Ray Dalio Sold Out
Frank Sands 9,380,802 sh (-8.22%)
John Griffin 595,000 sh (-25.63%)
» More
Q1 2017

BMRN Guru Trades in Q1 2017

Manning & Napier Advisors, Inc 1,692,470 sh (-16.54%)
Spiros Segalas 1,730,236 sh (-7.26%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:UCBJY, OTCPK:NVZMF, OTCPK:GIKLY, OTCPK:GMXAY, NAS:SGEN, NAS:ALKS, NAS:JAZZ, NAS:TSRO, OTCPK:SBMFF, NAS:EXEL, NAS:UTHR, NAS:BIVV, NAS:IONS, NAS:ARIA, NAS:ALNY, NAS:KITE, NAS:ACAD, NAS:GLPG, NAS:TECH, NAS:NBIX » details
Traded in other countries:BM8.Germany,
Headquarter Location:USA
Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme and Vimizim independently. BioMarin markets Kuvan--to treat the rare metabolic disorder PKU--in the U.S., and recently reacquired international rights for Kuvan and PKU drug candidate pegvaliase from Merck KGaA. BioMarin expanded its pipeline with acquisitions in 2010 (LEAD Therapeutics and Zystor) and 2015 (Prosensa).

Top Ranked Articles about Biomarin Pharmaceutical Inc

Low Valuation Ratios Lead to Strong Portfolio Returns Backtesting Ben Graham’s Lost Formula strategy
Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market. Read more...
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Investor reports latest quarterly portfolio
Samuel Isaly (Trades, Portfolio), manager of the Eaton Vance Worldwide Health Care Fund (ETHSX), invested in three health care companies and eliminated his position in three others during the second quarter of 2016. An active health care investor, Isaly seeks long-term capital growth in health care companies that have potential for high growth and increased market share. The portfolio manager generally has 80% of his assets in health sciences industries, including biotechnology, pharmaceuticals and medical equipment. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 400.00
BMRN's Forward PE Ratio is ranked lower than
99.99% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. BMRN: 400.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 5.50
BMRN's PB Ratio is ranked lower than
67% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. BMRN: 5.50 )
Ranked among companies with meaningful PB Ratio only.
BMRN' s PB Ratio Range Over the Past 10 Years
Min: 3.67  Med: 6.6 Max: 27.45
Current: 5.5
3.67
27.45
PS Ratio 13.04
BMRN's PS Ratio is ranked lower than
51% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. BMRN: 13.04 )
Ranked among companies with meaningful PS Ratio only.
BMRN' s PS Ratio Range Over the Past 10 Years
Min: 3.39  Med: 14.13 Max: 31.46
Current: 13.04
3.39
31.46
EV-to-EBIT -19.04
BMRN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. BMRN: -19.04 )
Ranked among companies with meaningful EV-to-EBIT only.
BMRN' s EV-to-EBIT Range Over the Past 10 Years
Min: -2242  Med: -58.1 Max: 305.6
Current: -19.04
-2242
305.6
EV-to-EBITDA -22.54
BMRN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. BMRN: -22.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMRN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25504  Med: -76.3 Max: 1532.3
Current: -22.54
-25504
1532.3
Current Ratio 3.24
BMRN's Current Ratio is ranked lower than
58% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. BMRN: 3.24 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 6.01 Max: 17.58
Current: 3.24
1.22
17.58
Quick Ratio 2.43
BMRN's Quick Ratio is ranked lower than
65% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. BMRN: 2.43 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 5.11 Max: 17.58
Current: 2.43
1.18
17.58
Days Inventory 556.42
BMRN's Days Inventory is ranked lower than
95% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BMRN: 556.42 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s Days Inventory Range Over the Past 10 Years
Min: 367.05  Med: 530.66 Max: 601.44
Current: 556.42
367.05
601.44
Days Sales Outstanding 70.36
BMRN's Days Sales Outstanding is ranked lower than
56% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. BMRN: 70.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.96  Med: 74.4 Max: 86.7
Current: 70.36
50.96
86.7

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.20
BMRN's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. BMRN: -6.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.6  Med: -9.05 Max: -3.2
Current: -6.2
-32.6
-3.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 92.15
BMRN's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. BMRN: 92.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BMRN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.51  Med: 16.48 Max: 208.24
Current: 92.15
5.51
208.24
Price-to-Tangible-Book 7.55
BMRN's Price-to-Tangible-Book is ranked lower than
70% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. BMRN: 7.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMRN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.85  Med: 7.23 Max: 21.92
Current: 7.55
3.85
21.92
Price-to-Median-PS-Value 0.92
BMRN's Price-to-Median-PS-Value is ranked higher than
59% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BMRN: 0.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMRN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.3 Max: 4.47
Current: 0.92
0.41
4.47
Earnings Yield (Greenblatt) % -5.25
BMRN's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. BMRN: -5.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMRN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 1.2 Max: 4
Current: -5.25
0.3
4

More Statistics

Revenue (TTM) (Mil) $1,117
EPS (TTM) $ -3.84
Beta2.05
Short Percentage of Float4.33%
52-Week Range $73.45 - 102.49
Shares Outstanding (Mil)172.87

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,301 1,471 1,689
EPS ($) -0.16 0.35 1.09
EPS without NRI ($) -0.16 0.35 1.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
28.00%
Dividends per Share ($)
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treat Apr 21 2017 
BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 Apr 20 2017 
BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement Apr 13 2017 
Piotroski F-Score in the Real World Dec 19 2016 
U.S. Elections: What They Might Mean for Investors - JOHCM Commentary Nov 29 2016 
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Spiros Segalas Buys McDonald's, Microsoft, Alibaba May 05 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 

More From Other Websites
BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First... Apr 21 2017
BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4... Apr 20 2017
Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed Apr 19 2017
5 Drug Stocks That Could Be Big Winners this Earnings Season Apr 17 2017
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US :... Apr 14 2017
The Hot Stock: Alexion Pharmaceuticals Climbs 3.3% Apr 13 2017
BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement Apr 13 2017
Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride Apr 12 2017
3 Stocks We'd Buy and Hold for the Next 20 Years Apr 06 2017
Just How Much Is a Medical Miracle Worth? Apr 06 2017
4 FDA Decisions to Watch Out for in Apr 2017 Apr 03 2017
4 Drug Stocks With Big News Coming in April Apr 02 2017
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US :... Mar 30 2017
Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report? Mar 28 2017
Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse Mar 23 2017
Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next Mar 16 2017
Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store? Mar 06 2017
Biotechs Leap On Trump's Calls For Innovation, Speedy FDA Approval Mar 01 2017
Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals Mar 01 2017
BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017 Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)